What is Solvemed?
Operating within the high-growth Information Technology and Services sector, Solvemed specializes in the development of first-in-class digital biomarkers. These tools are designed to provide objective, data-driven insights that support the development of novel neurological therapeutics while simultaneously establishing affordable, scalable solutions for clinical examination and remote patient monitoring. By bridging the gap between computational biology and clinical practice, the company addresses a critical market need for more precise, accessible diagnostic and monitoring frameworks in an aging global population. Their approach represents a significant shift from traditional, subjective assessment methods toward a more rigorous, technology-enabled standard of care.
How much funding has Solvemed raised?
Solvemed has raised a total of $3.5M across 1 funding round:
Other Financing Round
$3.5M
Other Financing Round (2022): $3.5M with participation from Tensor Ventures, APEX Ventures, Atmos Ventures, and Techni Ventures
Key Investors in Solvemed
Tensor Ventures
Tensor Ventures is a next-generation venture capital firm that invests in combinatorial technologies, focusing on deep tech innovations such as AI, Quantum Technology, Computational Biotech, and Sustainable Tech.
APEX Ventures
APEX Ventures is a venture capital firm focused on deep-tech and medical innovations, aiming to build the next generation of world-leading companies through disruptive technology.
Atmos Ventures
ATMOS Ventures is a Deep Tech Venture Capital firm based in Central and Eastern Europe that invests in innovative teams and entrepreneurs tackling complex scientific challenges.
What's next for Solvemed?
With this major enterprise-level funding, Solvemed is well-positioned to scale its operational footprint and deepen its research capabilities. The strategic roadmap likely involves expanding the validation of its digital biomarker platform across diverse clinical cohorts and strengthening partnerships with pharmaceutical entities engaged in drug discovery. As the company transitions from its current development phase toward broader commercial integration, the focus will remain on refining its machine learning models to ensure high-fidelity data output. This capital infusion provides the necessary runway to navigate the regulatory landscape and solidify Solvemed's status as a critical infrastructure provider in the global neuro-tech ecosystem.
See full Solvemed company page
